Abstract
Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.
Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Volume: 9 Issue: 1
Author(s): M. Matsuyama and R. Yoshimura
Affiliation:
Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer
Abstract: Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.
Export Options
About this article
Cite this article as:
Matsuyama M. and Yoshimura R., A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/187153009787582432
DOI https://dx.doi.org/10.2174/187153009787582432 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Anti-Cancer Effects of Asiatic Acid, a Triterpene from Centilla asiatica L: A Review
Anti-Cancer Agents in Medicinal Chemistry Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Does Erythropoietin Always Win?
Current Medicinal Chemistry Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
Anti-Cancer Agents in Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Current Cancer Therapy Reviews TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Matrix Systems for siRNA Delivery
Current Topics in Medicinal Chemistry Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry